Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Lung Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03998189 | Metabolic and Microbial Profiling of Lung Cancer | N/A | terminated | Jun 26, 2019 | Wake Forest University Health Sciences | Study deemed no longer feasible | Other (stated, no rule matched) |
| NCT05007769 | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in…(RAN) | Phase 2 | withdrawn | Aug 16, 2021 | Washington University School of Medicine | Lost funding | Funding |
| NCT04262869 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV… | Phase 2 | withdrawn | Feb 10, 2020 | Emory University | Due to accrual issues | Enrollment / accrual |
| NCT01741155 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With… | Phase 2 | terminated | Dec 4, 2012 | Spectrum Pharmaceuticals, Inc | The study did not meet efficacy end point and did not enroll patients in the randomized phase. | Efficacy / futility |
| NCT01799135 | Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC) | N/A | terminated | Feb 26, 2013 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin…(SHERLOC) | Phase 2 | terminated | Mar 12, 2015 | Elevation Oncology | Based on the preliminary results seen during interim analysis, which were confirmed in the final… | Efficacy / futility |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With… | Early Phase 1 | withdrawn | Dec 21, 2020 | Fox Chase Cancer Center | Grantor shifted focus in disease, funding was stopped | Funding |
| NCT01288430 | A Study of DS-2248 in Participants With Advanced Solid Tumors | Phase 1 | terminated | Feb 2, 2011 | Daiichi Sankyo | The trial was terminated as per Sponsor decision. | Sponsor / business decision |
| NCT03624907 | Daily vs. Non-Daily SBRT for NSCLC | N/A | terminated | Aug 10, 2018 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid… | Phase 1 / Phase 2 | terminated | Apr 27, 2017 | Dana-Farber Cancer Institute | Study closed due to slow accrual and lack of efficacy. | Efficacy / futility |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung… | Phase 1 / Phase 2 | terminated | Apr 3, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT04160559 | Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung… | N/A | withdrawn | Nov 13, 2019 | Xinqiao Hospital of Chongqing | There are no suitable participants | Other (stated, no rule matched) |
| NCT03431415 | Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b)…(RAXSIA) | N/A | withdrawn | Feb 13, 2018 | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Accrual issues | Enrollment / accrual |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2020 | NextCure, Inc. | Upon reviewing current available combo studies, the sponsor decided to prioritize different combo… | Sponsor / business decision |
| NCT04085081 | Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer… | N/A | withdrawn | Sep 11, 2019 | City of Hope Medical Center | Funding issue | Funding |
| NCT03245177 | Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung…(PARIS) | Phase 1 | withdrawn | Aug 10, 2017 | Prof Corinne Faivre-Finn | Funding withdrawn. | Funding |
| NCT03200600 | Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery | Phase 4 | terminated | Jun 27, 2017 | Peking University First Hospital | Protocol violation occurred frequently during the postoperative period. | Other (stated, no rule matched) |
| NCT01108666 | Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage… | Phase 2 | terminated | Apr 22, 2010 | Abramson Cancer Center at Penn Medicine | Insufficient accrual | Enrollment / accrual |
| NCT04289259 | Tumor Mutational Burden in Lung Cancer Patients(MUBULUC) | — | terminated | Feb 28, 2020 | Assistance Publique - Hôpitaux de Paris | The funder stopped to fund this study. | Funding |
| NCT04611776 | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy,…(CATHAYA) | Phase 2 | withdrawn | Nov 2, 2020 | Hoffmann-La Roche | The positive results from IMpower010 demonstrated benefit by adding atezolizumab as adjuvant… | Enrollment / accrual |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | Phase 1 / Phase 2 | terminated | Jan 29, 2015 | Pfizer | The study was ended for strategic reasons and changes in the external environment. The safety… | Safety / toxicity |
| NCT02768558 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced… | Phase 3 | terminated | May 11, 2016 | RTOG Foundation, Inc. | Another treatment found efficacious | Other (stated, no rule matched) |
| NCT02274038 | Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for… | N/A | terminated | Oct 24, 2014 | University of Pennsylvania | Poor Accrual | Enrollment / accrual |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV… | Phase 2 | terminated | Dec 3, 2015 | Henan Cancer Hospital | As there are so many clinical trials in progress and the number of patients enrolled limited. | Enrollment / accrual |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT00380666 | The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small… | N/A | withdrawn | Sep 26, 2006 | University of Aarhus | Technical problems. | Other (stated, no rule matched) |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase 1 / Phase 2 | withdrawn | Jan 16, 2014 | Jazz Pharmaceuticals | Protocol not activated. | Other (stated, no rule matched) |
| NCT04835025 | Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung… | — | suspended | Apr 8, 2021 | Tongji Hospital | because of COVID-19 | COVID-19 / pandemic |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of… | Phase 3 | terminated | Nov 19, 2010 | Daiichi Sankyo | Sponsor decision due to the protocol-defined stopping boundary for futility was met based on the… | Efficacy / futility |
| NCT04069442 | cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving…(LUNG-PREDICT) | — | withdrawn | Aug 28, 2019 | University Hospital, Grenoble | access to human body samples by another existing cohort | Other (stated, no rule matched) |
| NCT01237171 | A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non… | — | withdrawn | Nov 9, 2010 | IsoRay Medical, Inc. | Study never moved past ideation phase | Other (stated, no rule matched) |
| NCT03644823 | Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced…(COM-IT-1) | Phase 2 | terminated | Aug 23, 2018 | Oslo University Hospital | slow recruiting | Enrollment / accrual |
| NCT02608528 | Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response… | — | terminated | Nov 18, 2015 | Abramson Cancer Center at Penn Medicine | Poor Accrual | Enrollment / accrual |
| NCT02132598 | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | Phase 2 | terminated | May 7, 2014 | Liza Villaruz, MD | Trial stopped due to slow patient accrual. | Enrollment / accrual |
| NCT01212627 | Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer | Phase 1 | terminated | Sep 30, 2010 | Angela Taber MD | Determination to stop enrollment made due to funding | Enrollment / accrual |
| NCT04274907 | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult… | Phase 1 | terminated | Feb 18, 2020 | AbbVie | Company Decision | Sponsor / business decision |
| NCT02400424 | Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor(GFPC_01-14) | N/A | terminated | Mar 27, 2015 | Centre Leon Berard | Approval of adjuvant durvalumab after RT-CT (not anticipated in the study design) and small number… | Other (stated, no rule matched) |
| NCT03256721 | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment… | Phase 2 | terminated | Aug 22, 2017 | Fuzhou General Hospital | Due to the enrollment was slow and exceeded the expected enrollment time | Enrollment / accrual |
| NCT04267237 | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus… | Phase 2 | withdrawn | Feb 12, 2020 | Hoffmann-La Roche | Accrual timelines | Enrollment / accrual |
| NCT02893332 | Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung…(Sindas) | Phase 3 | terminated | Sep 8, 2016 | Sichuan Provincial People's Hospital | After interim analysis, IRB recommend termination. | Efficacy / futility |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth… | Phase 1 | terminated | Apr 24, 2017 | ADC Therapeutics S.A. | Safety | Safety / toxicity |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT02262000 | Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer(SABR) | N/A | terminated | Oct 10, 2014 | West Virginia University | Investigator left institution | Investigator |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive… | Phase 2 | terminated | Jun 30, 2015 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT03382899 | Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone…(Cypress 1) | Phase 2 | terminated | Dec 26, 2017 | Eli Lilly and Company | The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit… | Other (stated, no rule matched) |
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC(RADFORMIN) | Phase 2 | terminated | Nov 20, 2019 | ethisch.comite@uza.be | Loss of external funding | Funding |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on… | Phase 2 | terminated | Sep 26, 2008 | Hoffmann-La Roche | The study was terminated due to the termination of the clinical development program. | Other (stated, no rule matched) |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment…(ATRACT-1) | Phase 3 | terminated | Apr 21, 2008 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00738387 | A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for…(ATTRACT-2) | Phase 3 | terminated | Aug 20, 2008 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced… | Phase 1 / Phase 2 | terminated | Dec 29, 2010 | MedImmune LLC | In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 5, 2021source: clinicaltrials